Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C

Article English OPEN
Manolakopoulos, Spilios; Zacharakis, George; Zissis, Miltiadis; Giannakopoulos, Vassilis;
  • Publisher: Hellenic Society of Gastroenterology
  • Journal: Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology,volume 29,issue 3,pages282-296 (issn: 1108-7471, eissn: 1792-7463)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.20524/aog.2016.0041, pmc: PMC4923813
  • Subject: treatment | Review Article | chronic hepatitis C | Daclatasvir
    mesheuropmc: virus diseases | digestive system diseases

Daclatasvir (Daklinza™), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic... View more
Share - Bookmark